Aziyo Biologics (NASDAQ:AZYO) versus LadRx (OTCMKTS:CYTR) Head to Head Review

Aziyo Biologics (NASDAQ:AZYO – Get Rating) and LadRx (OTCMKTS:CYTR – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of current ratings for Aziyo Biologics and LadRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aziyo Biologics	0	0	3	0	3.00
LadRx	0	0	0	0	N/A

Aziyo Biologics presently has a consensus price target of $10.25, suggesting a potential upside of 142.42%.

Insider and Institutional Ownership

64.9% of Aziyo Biologics shares are owned by institutional investors. Comparatively, 0.1% of LadRx shares are owned by institutional investors. 39.9% of Aziyo Biologics shares are owned by company insiders. Comparatively, 12.8% of LadRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Aziyo Biologics and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aziyo Biologics	-77.08%	-1,819.23%	-60.62%
LadRx	N/A	-67.61%	-45.39%

Volatility and Risk

Aziyo Biologics has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.

Earnings and Valuation

This table compares Aziyo Biologics and LadRx’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aziyo Biologics	$47.39 million	1.23	-$24.83 million	($2.84)	-1.49
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

LadRx has lower revenue, but higher earnings than Aziyo Biologics. Aziyo Biologics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Summary

LadRx beats Aziyo Biologics on 7 of the 11 factors compared between the two stocks.

About Aziyo Biologics

(Get Rating)

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

About LadRx

(Get Rating)

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.